Solomon Moshkevich Sells 1,026 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 1,026 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $146.04, for a total transaction of $149,837.04. Following the sale, the insider now directly owns 144,782 shares in the company, valued at approximately $21,143,963.28. This represents a 0.70 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Solomon Moshkevich also recently made the following trade(s):

• On Wednesday, March 5th, Solomon Moshkevich sold 6,000 shares of Natera stock. The shares were sold at an average price of $143.29, for a total transaction of $859,740.00.
• On Wednesday, January 29th, Solomon Moshkevich sold 5,201 shares of Natera stock. The shares were sold at an average price of $165.87, for a total transaction of $862,689.87.
• On Wednesday, January 22nd, Solomon Moshkevich sold 24,861 shares of Natera stock. The shares were sold at an average price of $164.97, for a total transaction of $4,101,319.17.

Natera Price Performance

Shares of NASDAQ NTRA traded up $4.59 during mid-day trading on Wednesday, reaching $150.87. The company’s stock had a trading volume of 2,162,925 shares, compared to its average volume of 1,349,026. The stock has a 50-day moving average of $162.25 and a two-hundred day moving average of $149.27. The stock has a market capitalization of $20.40 billion, a P/E ratio of -85.72 and a beta of 1.80. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. Natera, Inc. has a 1-year low of $83.13 and a 1-year high of $183.00.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.01. The business had revenue of $476.10 million during the quarter, compared to analysts’ expectations of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. On average, equities research analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Institutional Investors Weigh In On Natera

Hedge funds have recently modified their holdings of the business. Cerity Partners LLC grew its holdings in shares of Natera by 27.0% in the third quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company’s stock valued at $10,936,000 after purchasing an additional 18,316 shares during the period. Wilmington Savings Fund Society FSB purchased a new stake in shares of Natera in the third quarter valued at about $385,000. Everence Capital Management Inc. purchased a new stake in shares of Natera in the fourth quarter valued at about $573,000. Alpha DNA Investment Management LLC purchased a new stake in shares of Natera in the third quarter valued at about $505,000. Finally, First Turn Management LLC purchased a new stake in shares of Natera in the third quarter valued at about $19,760,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently commented on NTRA shares. BTIG Research reaffirmed a “buy” rating on shares of Natera in a report on Friday, February 28th. Barclays initiated coverage on shares of Natera in a research note on Thursday, January 23rd. They issued an “overweight” rating and a $200.00 target price for the company. JPMorgan Chase & Co. boosted their target price on shares of Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. Guggenheim boosted their target price on shares of Natera from $170.00 to $200.00 and gave the company a “buy” rating in a research note on Friday, January 17th. Finally, Sanford C. Bernstein boosted their target price on shares of Natera from $160.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, January 10th. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $178.12.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.